School of Medicine, Guizhou University, Guizhou, China.
Department of Oral and Maxillofacial Surgery, Guizhou Provincial People's Hospital, Guizhou, China.
Biosci Rep. 2021 Jan 29;41(1). doi: 10.1042/BSR20201533.
Immune infiltration in Prostate Cancer (PCa) was reported to be strongly associated with clinical outcomes. However, previous research could not elucidate the diversity of different immune cell types that contribute to the functioning of the immune response system. In the present study, the CIBERSORT method was employed to evaluate the relative proportions of immune cell profiling in PCa samples, adjacent tumor samples and normal samples. Three types of molecular classification were identified in tumor samples using the 'CancerSubtypes' package of the R software. Each subtype had specific molecular and clinical characteristics. In addition, functional enrichment was analyzed in each subtype. The submap and Tumor Immune Dysfunction and Exclusion (TIDE) algorithms were also used to predict clinical response to the immune checkpoint blockade. Moreover, the Genomics of Drug Sensitivity in Cancer (GDSC) database was employed to screen for potential chemotherapeutic targets for the treatment of PCa. The results showed that Cluster I was associated with advanced PCa and was more likely to respond to immunotherapy. The findings demonstrated that differences in immune responses may be important drivers of PCa progression and response to treatment. Therefore, this comprehensive assessment of the 22 immune cell types in the PCa Tumor Environment (TEM) provides insights on the mechanisms of tumor response to immunotherapy and may help clinicians explore the development of new drugs.
免疫浸润在前列腺癌（PCa）中被报道与临床结局密切相关。然而，先前的研究无法阐明不同免疫细胞类型的多样性，这些细胞类型对免疫反应系统的功能有贡献。在本研究中，使用 CIBERSORT 方法评估了 PCa 样本、相邻肿瘤样本和正常样本中免疫细胞谱的相对比例。使用 R 软件的“CancerSubtypes”包在肿瘤样本中确定了三种类型的分子分类。每种亚型都具有特定的分子和临床特征。此外，还对每个亚型进行了功能富集分析。还使用 submap 和 Tumor Immune Dysfunction and Exclusion (TIDE) 算法预测免疫检查点阻断的临床反应。此外，还使用癌症药物敏感性基因组学 (GDSC) 数据库筛选用于治疗 PCa 的潜在化疗靶点。结果表明，Cluster I 与晚期 PCa 相关，并且更有可能对免疫治疗有反应。研究结果表明，免疫反应的差异可能是 PCa 进展和对治疗反应的重要驱动因素。因此，对 PCa 肿瘤环境（TEM）中 22 种免疫细胞类型的全面评估提供了对肿瘤对免疫治疗反应机制的深入了解，并可能有助于临床医生探索新药物的开发。
